DnB Asset Management
MLTX icon

DnB Asset Management’s MoonLake Immunotherapeutics MLTX Stock Holding History

DnB Asset Management’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-9,585
Closed -$452K – 751
2025
Q2 		$452K Sell
9,585
-726
-7% -$29.6K ﹤0.01% 657
2025
Q1 		$403K Buy
10,311
+1,955
+23% +$84.2K ﹤0.01% 671
2024
Q4 		$452K Buy
8,356
+847
+11% +$43.2K ﹤0.01% 668
2024
Q3 		$379K Buy
7,509
+137
+2% +$6.42K ﹤0.01% 670
2024
Q2 		$324K Buy
7,372
+1,694
+30% +$71.8K ﹤0.01% 671
2024
Q1 		$285K Buy
+5,678
New +$308K ﹤0.01% 679

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

DnB Asset Management's MLTX Position: Q3 2025 in Review

DnB Asset Management sold out of MoonLake Immunotherapeutics (MLTX) in Q3 2025, closing a stake of 9,585 shares — an estimated $452K sold.

DnB Asset Management first reported a position in MLTX in Q1 2024 and held it in 6 quarters. The position peaked at $452K in Q4 2024. 134 funds tracked by Wall St. Rank hold MLTX as of Q3 2025.

  • DnB Asset Management reported no remaining MoonLake Immunotherapeutics position as of Q3 2025 after selling out during the quarter.
  • DnB Asset Management sold 9,585 MoonLake Immunotherapeutics shares in Q3 2025, an estimated $452K.
  • DnB Asset Management first reported a position in MoonLake Immunotherapeutics in Q1 2024 and held it in 6 quarters.
  • DnB Asset Management's MoonLake Immunotherapeutics position peaked at $452K in Q4 2024.
  • 134 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q3 2025.

Based on DnB Asset Management's 13F filing for Q3 2025, filed 12 Nov 2025.